Barclays raised the firm’s price target on Omada Health (OMDA) to $28 from $24 and keeps an Overweight rating on the shares ahead of the earnings report on November 6. The firm expects another “beat and raise” quarter based on seasonal trends, adoption of the company’s higher priced programs, growing GLP-1 use.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OMDA:
- Omada Health’s Surge in App Downloads and GLP-1 Care Track Expansion Justify Buy Rating
- Omada Health added to ‘Tactical Outperform’ list at Evercore ISI
- Omada Health launches “Meal Map” AI-powered nutrition tool
- Omada Health announces analysis on weight maintenance post GLP-1 discontinuation
- Omada Health initiated with a Neutral at Baird